NEW YORK, Jan. 27, 2015 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, today announced a license agreement for the indication of Diabetes Mellitus.
Invigorcell will be filing an IND with the FDA for the indication of Diabetes Mellitus.
According to Dr. Steven Victor CEO, "We are pleased to license the indication of Diabetes Mellitus to Invigorcell who will be conducting an IND with the FDA. With Joe Krivulka and Marc Sandberg MD leading the way I am sure we will see positive results with the FDA in a short period of time, and be able to change the lives of millions of diabetic patients."
Marc Sandberg, M.D., "Diabetes has both a huge financial and personal burden around the world. Restoring both Beta Cell and Metabolic function using Stromal Vascular Fraction Cells derived from blood vessels found in adipose tissue has a great potential to relieve suffering of people and improve economies."
About IntelliCell BioSciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, Universities, and international business entities.
Invigorcell is a biotech company that will utilize the technologies of IntelliCell BioSciences to develop innovative treatments for the normalization of metabolism in both Type 1 and Type 2 diabetes. Invigorcell is lead by Marc I. Sandberg, MD, FACP, CDE and Joe Krivulka.
Dr. Sandberg is a Clinical Assistant Professor in the Department of Internal Medicine at Temple University School of Medicine and is a certified diabetes Educator and board certified in Endocrinology, Diabetes and Metabolism. He is the medical director for the Center for Nutrition at Hunterdon Medical Center in Flemington, NJ. He practices general endocrinology and diabetes, and was recognized as a New Jersey Top Doc in 2005 and 2011-14. He has been involved in numerous Phase II-IV pharmaceutical trials, has served on several diabetes advisory product boards and lectures widely on diabetes.
Mr. Joseph J. Krivulka is Independent Director at Dance Biopharm, Inc., Chairman at Rouses Point Pharmaceuticals LLC, Chairman & Chief Executive Officer at Akrimax Pharmaceuticals LLC, and Independent Director at Nektar Therapeutics. Mr. Krivulka was previously employed as Chief Executive Officer by Triax Pharmaceuticals LLC, Independent Director by Aeolus Pharmaceuticals, Inc., President by Reliant Pharmaceuticals LLC, Chief Executive Officer by Bertek, Inc., and Vice President by Mylan Laboratories, Inc. He also served on the board at Ambrilia Biopharma, Inc., Biovail Corp., and Incara Pharmaceuticals Corp. He received his undergraduate degree from West Virginia Wesleyan College.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
IntelliCell BioSciences, Inc.
SOURCE IntelliCell BioSciences, Inc.